Guggenheim raised the firm’s price target on Zentalis (ZNTL) to $10 from $6 and keeps a Buy rating on the shares, citing increased probability of success assumptions in platinum-resistant ovarian cancer.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZNTL: